Steatotic hepatocellular carcinoma: Association of MRI findings to underlying liver disease and clinicopathological characteristics

Abstract

AbstractBackground & AimsFatty change is commonly observed in hepatocellular carcinoma (HCC); however, the characteristics of steatotic and steatohepatitic HCCs are not well understood.MethodsThis retrospective study included patients with HCCs who underwent resection between January 2014 and December 2019 to evaluate clinicopathological and magnetic resonance imaging features. Tumours were categorized as magnetic resonance imaging‐steatotic, pathology‐steatotic and steatohepatitic HCCs and were defined as HCCs with ≥50% steatosis on in‐and‐oppose phase images, ≥34% tumour cells with lipid droplets and ≥50% tumour areas with steatohepatitic features on light microscopy respectively.ResultsOf 465 HCCs, 38 (8%), 23 (5%) and 15 (3%) were diagnosed as magnetic resonance imaging‐steatotic, pathology‐steatotic and steatohepatitic HCCs respectively. These HCC variants were less likely to be associated with hepatitis B virus infections than with type 2 diabetes mellitus, metabolic syndrome, non‐tumour liver steatosis and steatohepatitis. Moreover, microvascular invasion was less likely to be associated with them than either tumour size or differentiation. Type 2 diabetes and non‐tumour steatosis were independent risk factors for magnetic resonance imaging‐steatotic HCCs. Pathology‐steatotic HCCs and steatohepatitic HCCs were significantly associated with magnetic resonance imaging‐steatotic HCCs. A targetoid appearance in the transitional or hepatobiliary phase was also more prevalent in steatohepatitic‐HCCs than in non–steatohepatitic‐HCCs. When magnetic resonance imaging‐steatotic HCCs were combined with one or more ancillary features, the sensitivity and specificity were 60% and 97% respectively.ConclusionUnderlying fatty liver disease and metabolic syndrome are strongly associated with both steatotic and steatohepatitic HCCs. Clinicoradiological characteristics help identify steatohepatitic HCC with high specificity.